|
|
|
Info: Your browser does not accept cookies. If you want to put products into your cart and purchase them you need to enable cookies.
Browse
Female Sexual Dysfunction: Prescription Drug Pipeline Overview
Female sexual dysfunction (FSD) affects an estimate 84 million women across the seven major pharmaceutical markets and represents a significant opportunity for investment. Despite its high prevalence, FSD is poorly understood and defined. Currently th
Commercial and Pipeline Insight: Infertility
This report provides full analysis of the current and future infertility drug market, with indication-specific forecasts to 2016 for marketed and key pipeline drugs. Analysis is supplemented with opinion leader comment
Stakeholder Opinions: Female Sexual Dysfunction
Patients in a clinical population receive drug and non-drug therapy for female sexual dysfunction, yet a third remain refractory to treatment, highlighting a need for a formally approved product for FSD. There is a low level of satisfaction with the c
HRT: Major Milestones - Current Perspectives on HRT & Menopause
The HRT market peaked in 2001 at $3.5 billion across the seven major markets. The Women`s Health Initiative findings released in 2002 showing that HRT use was associated with an increased breast cancer and cardiovascular disease risk precipitated a ma
Major Milestones: Female Sexual Dysfunction
Female sexual dysfunction affects an estimated 84 million women across the seven major pharmaceutical markets and represents a significant opportunity for investment. The condition can affect a woman`s desire, ability to become aroused and orgasm and
The World Market for Sexual Disorders, 2005-2012
The report provides a detailed analysis of the sexual disorders therapy area to include insights for product extension and reformulation, sales forecasts to 2012, and impact of late-stage pipeline drugs on the market.
Stakeholder Opinions: Hormonal Contraceptives
The hormonal contraceptive market grew by 4.2% from 2004 to $5.0 billion in 2005. Market growth was driven in part by the strong uptake of Schering AG’s Yasmin and Organon’s NuvaRing which fulfill key strategies: additional indications and
Stakeholder Opinion: Erectile Dysfunction
The erectile dysfunction market grew 3.5% from 2005 to be worth $1.95 billion in 2005 and is almost entirely composed of sales from three brands: Viagra (sildenafil), Cialis (tadalafil) and Levitra (vardenafil). Despite the dominance of these products
Results 1 - 13 of 13
|
|
|
|
